AGTX
Agentix Corp.Company Information
- Company Name
- Agentix Corp.
- CIK
- CIK0001603345
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- AGTX: OTC
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- AGTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2020-03-29
- Last sale
- 2019-11-22
- Shares purchased (TTM)
- 935,716
- Shares sold (TTM)
- 18,448
Institutional Sentiment
- As of
- —
- Institutional shares owned
- —
- Shares outstanding
- —
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Commitments And Contingencies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -4 | -4 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | ||||||
| Common Stock Shares Subscriptions | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | ||||||
| Additional Paid In Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | - | 0 | - | - | ||||||
| Retained Earnings Accumulated Deficit | -7 | -7 | -7 | -7 | -7 | -7 | -6 | -6 | -6 | -6 | -6 | -6 | ||||||
| Accumulated Other Comprehensive Income Loss Before Tax1 | - | - | - | - | - | - | - | - | -0 | - | -0 | 0 | ||||||
| Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | ||||||
| Shares Outstanding | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | ||||||
| Common Stock Capital Shares Reserved For Future Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAgentix Corp. (AGTX) — SEC Financial Statements & Analysis
Agentix Corp. (AGTX) is a biological products, (no diagnostic substances) company, incorporated in NV. Agentix Corp. trades on OTC as: AGTX. Agentix Corp. (AGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Agentix Corp. carries a market cap of $801.34K, a P/E ratio of -1.65x, a P/B ratio of -0.22x, an enterprise value of $801.30K, and an EV/EBITDA multiple of -1.80x. On profitability, it posts a Return on Equity (ROE) of 13.90% and a Return on Assets (ROA) of -21826.34%. Per share, it reports EPS of $-0.01, diluted EPS of $-0.01, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -14.36% year-over-year and EPS growth of -14.36% year-over-year. On the balance sheet, it maintains a current ratio of 0.00x, a quick ratio of 0.00x, working capital of $-3.71M, a debt-to-equity ratio of -1.00x, a debt ratio of 97.73K, an interest coverage ratio of -5.56x, free cash flow of $-108.53K (TTM), and net debt of $-38. Figures sourced from SEC EDGAR.
- Market Cap
- $801.34K
- P/E TTM
- -1.65x
- EPS TTM
- $-0.01
- P/B TTM
- -0.22x
- ROE TTM
- 13.90%
- ROA TTM
- -21826.34%
- Debt To Equity
- -1.00x
- Free Cash Flow TTM
- $-108.53K
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Agentix Corp. in?
Agentix Corp. (AGTX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does AGTX trade on?
Agentix Corp. (AGTX) trades on the OTC.
Where is Agentix Corp. incorporated?
Agentix Corp. is incorporated in NV.
When was Agentix Corp. (AGTX)'s most recent SEC filing?
Agentix Corp. (AGTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is AGTX's market cap?
Agentix Corp. (AGTX) has a market capitalization of $801.34K as of 2026-06-30.
What is AGTX's EPS (earnings per share)?
Agentix Corp. (AGTX)'s trailing twelve month EPS is $-0.01 as of 2026-06-30.
What is AGTX's ROE (return on equity)?
Agentix Corp. (AGTX)'s trailing twelve month Return on Equity (ROE) is 13.90% as of 2026-06-30.
What is AGTX's ROA (return on assets)?
Agentix Corp. (AGTX)'s trailing twelve month Return on Assets (ROA) is -21826.34% as of 2026-06-30.
What is AGTX's EV/EBITDA?
Agentix Corp. (AGTX)'s trailing twelve month EV/EBITDA is -1.80x as of 2026-06-30.